WEBULL
News
LPCN
8.72
-1.02%
-0.09
Weekly Report: what happened at LPCN last week (0202-0206)?
Weekly Report · 2d ago
Weekly Report: what happened at LPCN last week (0126-0130)?
Weekly Report · 02/02 10:00
Weekly Report: what happened at LPCN last week (0119-0123)?
Weekly Report · 01/26 10:00
Lipocine Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 01/21 11:41
Lipocine Price Target Raised to $15.00/Share From $7.00 by HC Wainwright & Co.
Dow Jones · 01/21 11:41
HC Wainwright & Co. Maintains Buy on Lipocine, Raises Price Target to $15
Benzinga · 01/21 11:31
LIPOCINE, INC. <LPCN.O>: H.C. WAINWRIGHT RAISES TARGET PRICE TO $15 FROM $7
Reuters · 01/21 11:07
U.S. RESEARCH ROUNDUP-IBM, KLA, WEX
Reuters · 01/21 08:26
Lipocine Completes Phase 3 Enrollment for Postpartum Depression Drug
TipRanks · 01/20 14:59
Lipocine Completes Enrollment, Patient Dosing In Its Phase 3 Clinical Study Of LPCN 1154 To Treat Postpartum Depression
Benzinga · 01/20 13:10
Lipocine Completes Enrollment in Phase 3 Trial of LPCN 1154 for Postpartum Depression
Reuters · 01/20 13:03
LIPOCINE INC - TOPLINE RESULTS EXPECTED EARLY Q2 2026
Reuters · 01/20 13:00
Weekly Report: what happened at LPCN last week (0112-0116)?
Weekly Report · 01/19 10:05
Lipocine updates investor presentation and corporate materials
TipRanks · 01/12 21:48
Lipocine Advances Phase 3 Postpartum Depression Drug Trial
TipRanks · 01/12 15:01
Lipocine Completes Scheduled Independent Data Safety Monitoring Board Review Of Ongoing Phase 3 Clinical Trial evaluating LPCN 1154 For Rapid Relief Treatment Of PPD.
Benzinga · 01/12 13:18
Lipocine: DSMB recommended Phase 3 LPCN 1154 continue as planned
TipRanks · 01/12 13:16
Lipocine Completes Phase 3 Safety Review of LPCN 1154 for Postpartum Depression
Reuters · 01/12 13:03
LIPOCINE INC: ON TRACK TO REPORT TOPLINE RESULTS EARLY IN Q2 OF 2026
Reuters · 01/12 13:00
More
Webull provides a variety of real-time LPCN stock news. You can receive the latest news about Lipocine Inc through multiple platforms. This information may help you make smarter investment decisions.
About LPCN
Lipocine Inc. is a biopharmaceutical company leveraging its proprietary technology platform to enable effective oral delivery of therapeutics. The Company’s clinical development candidates include: LPCN 1154, oral brexanolone, for the treatment of postpartum depression, LPCN 2101, for the treatment of epilepsy, LPCN 2203, an oral candidate targeted for the management of essential tremor, LPCN 2401, an oral proprietary anabolic androgen receptor agonist for improved body composition in obesity management, and LPCN 1148, for the management of decompensated cirrhosis. It is also developing LPCN 1107, for the prevention of preterm birth, LPCN 1154, for rapid relief of postpartum depression, and LPCN 1144, for the treatment of metabolic dysfunction-associated steatohepatitis. Its product candidate, TLANDO, is a novel oral prodrug of testosterone containing testosterone undecanoate developed by the Company.